Literature DB >> 9398742

Telomerase activity in human thyroid carcinomas originating from the follicular cells.

P Brousset1, N Chaouche, F Leprat, F Branet-Brousset, H Trouette, R C Zenou, J P Merlio, G Delsol.   

Abstract

Telomerase activity is known to be absent from most normal and well-differentiated tissues, although being detectable in the vast majority of malignant tumors. An increasing number of reports demonstrate that telomerase may be activated in benign tumors, such as adenomas. We have investigated a series of normal and neoplastic thyroid tissues for the presence of telomerase activity. As expected, all normal thyroid tissues (n = 20) had no display of telomerase activity. Amongst cancers, the incidence of telomerase activity varied with the histological subtypes. Telomerase activity was present in only 3/15 cases (20%) of papillary carcinomas. Telomerase activity was more frequently detected in follicular (4/6) and in undifferentiated (2/3) carcinomas. Unexpectedly, one case (1/12) of adenoma contained high levels of telomerase activity. Taken together, these results indicate that telomerase may play some role in the pathogenesis of thyroid tumors, in particular in follicular and undifferentiated carcinomas that are known to have the most aggressive behavior.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9398742     DOI: 10.1210/jcem.82.12.4401

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Coding Molecular Determinants of Thyroid Cancer Development and Progression.

Authors:  Veronica Valvo; Carmelo Nucera
Journal:  Endocrinol Metab Clin North Am       Date:  2018-12-23       Impact factor: 4.741

2.  Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

Authors:  Iñigo Landa; Ian Ganly; Timothy A Chan; Norisato Mitsutake; Michiko Matsuse; Tihana Ibrahimpasic; Ronald A Ghossein; James A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2013-07-05       Impact factor: 5.958

Review 3.  Molecular diagnostic tests in the diagnosis and management of thyroid carcinoma.

Authors:  M D Ringel
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

4.  Telomeres and thyroid cancer.

Authors:  Marco Capezzone; Stefania Marchisotta; Silvia Cantara; Furio Pacini
Journal:  Curr Genomics       Date:  2009-12       Impact factor: 2.236

5.  Telomerase activity in well-differentiated papillary thyroid carcinoma correlates with advanced clinical stage of the disease.

Authors:  Leticia Bornstein-Quevedo; M L García-Hernández; Ignacio Camacho-Arroyo; Miguel F Herrera; Arturo Angeles Angeles; Ofelia González Treviño; Armando Gamboa-Domínguez
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

6.  Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas.

Authors:  Paula Soares; Jorge Lima; Ana Preto; Patricia Castro; João Vinagre; Ricardo Celestino; Joana P Couto; Hugo Prazeres; Catarina Eloy; Valdemar Máximo; M Sobrinho-Simões
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

Review 7.  Telomeres and telomerase in endocrine pathology.

Authors:  G Kontogeorgos; K Kovacs
Journal:  Endocrine       Date:  1998-10       Impact factor: 3.925

8.  Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines.

Authors:  Brittany A Avin; Yongchun Wang; Timothy Gilpatrick; Rachael E Workman; Isac Lee; Winston Timp; Christopher B Umbricht; Martha A Zeiger
Journal:  Genes Chromosomes Cancer       Date:  2019-02-10       Impact factor: 4.263

9.  TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.

Authors:  Miguel Melo; Adriana Gaspar da Rocha; João Vinagre; Rui Batista; Joana Peixoto; Catarina Tavares; Ricardo Celestino; Ana Almeida; Catarina Salgado; Catarina Eloy; Patrícia Castro; Hugo Prazeres; Jorge Lima; Teresina Amaro; Cláudia Lobo; Maria João Martins; Margarida Moura; Branca Cavaco; Valeriano Leite; José Manuel Cameselle-Teijeiro; Francisco Carrilho; Manuela Carvalheiro; Valdemar Máximo; Manuel Sobrinho-Simões; Paula Soares
Journal:  J Clin Endocrinol Metab       Date:  2014-01-29       Impact factor: 5.958

10.  Functional evaluation of TERT-CLPTM1L genetic variants associated with susceptibility of papillary thyroid carcinoma.

Authors:  Minghua Ge; Meng Shi; Changming An; Wenjun Yang; Xilin Nie; Jian Zhang; Zheng Lv; Jinliang Li; Liqing Zhou; Zhongli Du; Ming Yang
Journal:  Sci Rep       Date:  2016-05-17       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.